Arrowhead Pharmaceuticals
ARWR · Biotechnology
$58.02
0.6%Halozyme
HALO · Biotechnology
$125.63
0.9%The short version
- Halozyme is the larger business, with $1.4B of revenue in fiscal 2025 against $829M for Arrowhead Pharmaceuticals, about 1.7 times as much.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 37.6%).
- Halozyme kept more of each dollar of sales as operating profit (33.6% operating margin, against 11.9% operating margin).
- Halozyme turned more of its sales into free cash flow (46.2% FCF margin, against 18.9% FCF margin).
| Latest fiscal year | ARWR · FY25 | HALO · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | $15.2B |
| Revenue | $829M | $1.4B |
| Free cash flow | $157M | $645M |
| Net income | −$1.6M | $317M |
| Growth | ||
| Revenue growth | 23,258.2% | 37.6% |
| 5-year growth | 56.6% | 39.2% |
| Share count change | 11.7% | −4.3% |
| Profitability | ||
| Gross margin | — | 83.6% |
| Operating margin | 11.9% | 33.6% |
| Net margin | −0.2% | 22.7% |
| FCF margin | 18.9% | 46.2% |
| Return on capital | — | 19.2% |
| Return on equity | −0.5% | 153.6% |
| Balance sheet | ||
| Net debt | −$665M | $2.0B |
| Net debt / EBITDA | −5.5x | 4.2x |
| Dividends and buybacks | $0.0M | $342M |
| Valuation & quality | ||
| P/E | — | 36.6x |
| Piotroski F-score | 5 | 5 |
FY16
ARWR $0.2M
HALO $147M
FY17
ARWR $31.4M
HALO $317M
FY18
ARWR $16.1M
HALO $152M
FY19
ARWR $169M
HALO $196M
FY20
ARWR $88.0M
HALO $268M
FY21
ARWR $138M
HALO $443M
FY22
ARWR $243M
HALO $660M
FY23
ARWR $241M
HALO $829M
FY24
ARWR $3.6M
HALO $1.0B
FY25
ARWR $829M
HALO $1.4B
ARWR
HALO
FY16
ARWR −51,627.1%
HALO −56.7%
FY17
ARWR −117.8%
HALO 25.6%
FY18
ARWR −346.5%
HALO −45.7%
FY19
ARWR 36.3%
HALO −34.5%
FY20
ARWR −105.9%
HALO 53.9%
FY21
ARWR −107.8%
HALO 62.2%
FY22
ARWR −73.4%
HALO 40.5%
FY23
ARWR −85.2%
HALO 40.7%
FY24
ARWR −16,927.1%
HALO 54.3%
FY25
ARWR 11.9%
HALO 33.6%
ARWR
HALO
FY16
ARWR −$68.3M
HALO −$53.5M
FY17
ARWR −$31.9M
HALO $133M
FY18
ARWR −$48.6M
HALO −$54.2M
FY19
ARWR $161M
HALO −$89.5M
FY20
ARWR −$108M
HALO $53.0M
FY21
ARWR $148M
HALO $298M
FY22
ARWR −$189M
HALO $235M
FY23
ARWR −$331M
HALO $373M
FY24
ARWR −$604M
HALO $468M
FY25
ARWR $157M
HALO $645M
ARWR
HALO
FY16
ARWR —
HALO −103.0%
FY17
ARWR −82.4%
HALO 61.2%
FY18
ARWR −70.2%
HALO −28.1%
FY19
ARWR 136.1%
HALO −38.2%
FY20
ARWR −57.6%
HALO —
FY21
ARWR −71.2%
HALO —
FY22
ARWR −69.1%
HALO 27.9%
FY23
ARWR −167.1%
HALO 21.3%
FY24
ARWR —
HALO 34.9%
FY25
ARWR —
HALO 19.2%
ARWR
HALO
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.